Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EPCAM
REST API REST API
Homo sapiens
EPCAM is differentially expressed in 244 experiments: 158 organism parts: lung, prostate, ... (156 more);, 212 disease states: normal, prostate carcinoma, ... (210 more);, 86 cell types 620 cell lines 18 compound treatments and 70 other conditions.
Synonyms MOC31, EGP-2, EGP34, EGP40, M4S1, Ly74, CO-17A, CD326, 323/A3, Ep-CAM, TROP1, GA733-2, KSA, MK-1, ESA, MIC18, TACST-1, TACSTD1, KS1/4, HEA125, 17-1A, MH99
Orthologs Epcam (Mus musculus)   TACSTD1 (Gallus gallus)   EPCAM (Bos taurus)   EPCAM (Danio rerio)   Epcam (Rattus norvegicus)   epcam (Xenopus laevis)   EPCAM (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, positive regulation of cell proliferation, tight junction, cell junction, basolateral plasma membrane, apical plasma membrane, integral to membrane, cell surface, lateral plasma membrane, ureteric bud development
InterPro Term Thyroglobulin_1
UniProt Accession P16422, B5MCA4, C9JKY3
Gene-Disease Assocation DIARRHEA 5, WITH TUFTING ENTEROPATHY, CONGENITAL; DIAR5, COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 8; HNPCC8
Search EB-eye ENSG00000119888
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-2549, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
LNCaP
2
E-GEOD-14464, E-GEOD-14990
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-MTAB-37, E-GEOD-15460
BT20
2
E-MTAB-37, E-MTAB-62
614 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (41 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
monocyte
2
E-GEOD-22373, E-GEOD-8286
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
leydig cell
1
E-MTAB-25
plasma cell
1
E-GEOD-6691
80 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-MTAB-62, E-GEOD-5418, ... (52 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
benign prostatic hyperplasia
3
E-MEXP-1243, E-GEOD-7307, E-GEOD-5377
gastric carcinoma
3
E-MTAB-37, E-GEOD-15460, E-GEOD-2685
prostate carcinoma
2
4
E-MTAB-62, E-MEXP-1327, E-TABM-26, E-MTAB-37, E-GEOD-7307, ... (6 experiments)
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-GEOD-6014
lymphoma
2
E-MTAB-37, E-MTAB-62
206 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-6907, E-GEOD-412, E-GEOD-2803, ... (11 experiments)

Factor Value U/D Experiments
none
1
2
E-GEOD-6907, E-GEOD-412, E-GEOD-2803
mannitol
1
E-GEOD-6400
nickel(II) chloride hexahydrate
1
E-GEOD-6907
unknown
1
E-GEOD-7307
Cxcl12
1
E-GEOD-7307
no estradiol
1
E-GEOD-20081
12 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
71
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-21589, E-GEOD-16363, E-GEOD-21610, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-361 ... (5 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-1446, E-GEOD-9764, E-GEOD-10315, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-GEOD-16363, ... (34 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-22541

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1309, E-GEOD-21750

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-15811

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.673 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM